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A B S T R A C T
In recent decades, the design of cocrystals has developed significantly due to the unique characteristics and
advantages of cocrystals, which help to improve the physicochemical properties of drugs, especially solubility.
Zwitterions are attractive and interesting co-formers. However, the physicochemical properties of cocrystals
with zwitterionic co-formers, i.e. zwitterionic cocrystals, have not been adequately evaluated. In this study,
solid-state characterization of a newly developed zwitterionic cocrystal of diclofenac (DFA), a non-steroidal anti-
inflammatory drug, and the amino acid L-proline (PRO) was performed using Fourier-transform infrared spec-
troscopy, differential scanning calorimetry, and powder X-ray diffraction (PXRD) analyses. In addition, the
crystal structure of the cocrystal (DFA-PRO) was determined by single-crystal X-ray diffraction analysis, after
which the zwitterionic structure was confirmed. The cocrystallization during co-grinding, which was in-
vestigated by PXRD, followed first-order kinetics. Furthermore, the solubility of the zwitterionic cocrystals was
7.5-times higher than that of the DFA crystals. The results indicate that the cocrystal is stable under ambient
conditions; however, it hydrates and transforms into a mixture of L-proline monohydrate crystals and DFA
crystals under conditions of high humidity.
1. Introduction
Cocrystal engineering is a method for developing the most desirable
physicochemical properties of drugs. It is used to optimize drug solu-
bility, dissolution, and absorption (Bhandaru et al., 2015; He et al.,
2016). Most cocrystals of medicinal compounds that have been studied
are either molecular or ionic (Duggirala et al., 2016). Zwitterionic co-
crystals are a special kind of cocrystals that are formed by hydrogen
bond interactions between a drug and a zwitterion co-former molecule.
Zwitterion co-formers allow for the formation of charge-assisted hy-
drogen bonds (Tilborg et al., 2014); therefore, zwitterionic cocrystal
designs provide promising results in the production of raw drug ma-
terials with better physicochemical properties.
The aim of this study was to design a pharmaceutical zwitterionic
cocrystal of the non-steroidal anti-inflammatory drug diclofenac in
order to improve its physicochemical properties, particularly solubility.
Diclofenac is widely used in both solid and liquid formulations (Barbato
et al., 2003). However, its effectiveness is limited by its low aqueous
solubility, which reduces its bioavailability in the body.
The zwitterion co-former selected for use in this study was L-proline
(PRO), which is a GRAS (Generally Regarded as Safe) compound and a
popular amino acid used in cocrystal research (Tilborg et al., 2013;
Othman et al., 2016; He et al., 2016; Liu et al., 2016). It is reported that
the 5-membered ring “lateral chain” in PRO renders the molecular
structure restricted and rigid (Tilborg et al., 2014). Cocrystals of the
following drugs and L-proline have been formulated and studied by
single-crystal X-ray diffraction (SCXRD): naproxen (Tilborg et al.,
2013), flurbiprofen (Silva et al., 2016), quercetin (He et al., 2016), and
nitrofurantoin (He et al., 2016). The chemical structures of diclofenac
acid (DFA) and L-proline (PRO) are presented in Fig. 1.
Diclofenac (pKa=4.18) is a weak acid that is mainly available in its
salt form (Fini et al., 2012). Its sodium, potassium (Williams and
Buvanendran, 2011), and alkyl-hydroxyl amine (Fini et al., 2010) salts
are the most common. Although the crystal structures of several DFA
cocrystals, such as DFA-isonicotinic amide (Báthori et al., 2011) and
DFA-theophylline (Surov et al., 2014), are known, there is no report on
the crystal structure of any of the zwitterionic cocrystals. Thus, in this
research, we aimed to characterize zwitterionic DFA-PRO cocrystal and
confirm its structure using various methods. The crystal structure of the
cocrystal was determined by SCXRD, which is used to explain the
https://doi.org/10.1016/j.ejps.2018.02.020
Received 8 November 2017; Received in revised form 4 February 2018; Accepted 19 February 2018
⁎ Corresponding author.
E-mail address: ilma_nugrahani@fa.itb.ac.id (I. Nugrahani).
European Journal of Pharmaceutical Sciences 117 (2018) 168–176
Available online 21 February 2018
0928-0987/ © 2018 Elsevier B.V. All rights reserved.
T
physicochemical properties of compounds. Furthermore, the kinetics of
cocrystallization during co-grinding was performed to fully study the
molecular interaction between DFA and PRO. A stability study was also
performed to investigate the impact of humidity on the storage of the
crystal. We believe that the data obtained in this study on the pro-
duction and stability of DFA-PRO will be valuable in the development
of new dosage forms.
2. Material and methods
2.1. Materials
Diclofenac sodium (purity, > 99%) was obtained from Phapros
(Jakarta, Indonesia). L-Proline monohydrate (purity,> 99%) was pur-
chased from Xi'an ZhongYun Biotechnology Co., Ltd. (XianYang,
China). Sodium chloride, potassium chloride, and potassium sulfate
were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).
All solvents used were purchased from E. Merck (Darmstadt, Germany).
DFA was obtained from the hydrolysis of diclofenac sodium using 1M
hydrochloric acid.
2.2. Methods
2.2.1. Cocrystal preparation
The cocrystal was prepared by mixing DFA with PRO at a stoi-
chiometric molar ratio of 1:1. The mixture was ground with a mortar
and pestle and kneaded, during which five drops of ethanol were added.
The kneading was continued until the powder was dry for about 30min.
Solvent addition was continuously repeated every 10min. A single
crystal of DFA-PRO was prepared by dissolving the kneaded product in
ethanol. The resulting solution was maintained to evaporate at the
ambient temperature in a sealed vial for five days, which yielded
needle-shaped crystals that were suitable for SCXRD analysis.
2.2.2. Fourier-transform infrared spectroscopy (FTIR) analysis
The FTIR spectra of the crystals were recorded using an infrared
spectrophotometer (4200 type A; JASCO, Easton, MD, USA) and a KBr
beam splitter. The KBr pellet method was used to obtain background
spectra. The range was set from 450 to 4000 cm−1 at 4 cm−1 resolu-
tion. The pure drug, co-former, and a physical mixture of the two
compounds were also analyzed by FTIR.
2.2.3. Differential scanning calorimetry (DSC)
Thermal property measurements were performed using DSC 8230L
(Rigaku Corporation, Tokyo, Japan) as follows. Approximately 5–10mg
of sample was accurately weighed and placed in an aluminum pan. The
sample pan was heated at a rate of 3 °C/min from 25 to 300 °C under a
nitrogen purge of 50mL/min. The empty aluminum pan was used as a
reference. All pans were closed during the analysis.
2.2.4. Powder X-ray diffraction (PXRD) analysis
PXRD was performed using a SmartLab X-ray diffractometer
(Rigaku Corporation). Each sample was placed between Mylar® films
prior to analysis. Powder pattern was collected from 2θ=3° to 40° at
ambient temperature at step and scan speeds of 0.01° and 3° min−1,
respectively, using a Cu-Kα source at 45 kV and 200mA.
2.2.5. SCXRD analysis and refinement
SCXRD data were collected at 93 K for the DFA-PRO crystals. The
measurement was carried out in ω-scan mode with an R-axis RAPID II
diffractometer (Rigaku) using the Cu-Kα radiation obtained from a
rotating anode source with a graphite monochromator. Integrated and
scaled data were empirically corrected for absorption effects using
ABSCOR (Higashi, 1995). The initial structure was solved using a dual-
space algorithm implemented in SHELXT (Sheldrick, 2015a) and re-
fined on F2 with SHELXL-2017/1 (Sheldrick, 2015b). All non-hydrogen
atoms were refined anisotropically. Hydrogen atoms attached to oxygen
or nitrogen atoms were located using the differential Fourier map and
refined isotropically. Other hydrogen atoms were determined geome-
trically and included in the calculation using the riding model. Mole-
cular graphics were produced using Mercury 3.7 (Bruno et al., 2002;
Macrae et al., 2006; Macrae et al., 2008).
2.2.6. Powder solubility study
An excess amount of DFA and DFA-PRO (1:1) cocrystal was pro-
duced by liquid-assisted grinding with the addition of several drops of
ethanol. The powder was suspended in 10mL of distilled water in
capped glass vials, after which the slurries obtained were agitated in an
orbital shaker (150 rpm/min) at room temperature for 24 h. Next, each
suspension was filtered through a paper filter and the amount of drug
solubilized was analyzed spectrophotometrically (UV–1800; Shimadzu,
Kyoto, Japan) at 275 nm. Each experiment was conducted in triplicate.
2.2.7. Kinetics of cocrystallization during co-grinding
Samples used in the kinetics of cocrystallization during co-grinding
experiment were prepared with an automatic grinder (mortar RM 100;
Retsch, Haan, Germany) at 5 scales with solvent addition. Grinding was
carried out for predefined time periods of 2 to 90min. The samples
were used in the investigation of the dynamics of interaction by PXRD
analysis.
Fig. 1. Chemical structures of (a) DFA and (b) PRO.
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2.2.8. Stability study
A simple cocrystal stability study was performed in jars that were
conditioned to equilibrate at 75%, 80%, and 90% relative humidity
(RH) using saturated sodium chloride, potassium chloride, and po-
tassium sulfate solutions, respectively. Each sample was then stored at
30 °C. The powder X-ray diffractograms of the cocrystals during storage
were then studied to evaluate changes in cocrystal amount in order to
assess deformation. Samples were taken at 2, 4, 12, and 24 h after
storage and assessed. Cocrystal percentage was determined using a
constructed calibration curve.
Cocrystal formation was calculated using PXRD quantitative
methods reported for blends of polymorphs (Qiu et al., 2015; Tiwari
et al., 2007). Calibration standards were prepared by blending DFA and
PRO in a 1:1M ratio with the required amount of DFA-PRO cocrystals.
The cocrystals used in the calibration were prepared by the solution
method described above. The total mass of each standard was 40mg.
The standards prepared contained 0%, 30%, 50%, 70%, or 100% (by
weight) of DFA-PRO cocrystals. The standards were prepared by
grinding each component individually for 2–3min at room temperature
in a mill. This was done to reduce particle size differences between
these components and to obtain a homogeneous blend for the stan-
dards. The samples were also prepared by grinding them for 2–3min.
The standards and the samples were then analyzed using the SmartLab
X-ray diffractometer. Quantitative estimations were done using a curve-
fitting algorithm with a Gaussian-Lorentzian function. The proportion
of the corresponding peak was stated as area under the curve. The ca-
libration curve obtained was then validated using the parameter stan-
dards. The R2 value for each calibration curve was 0.99. The calibration
curve was used to determine the amount (%) of cocrystal during the
grinding process and storage.
2.3. Results and discussion
2.3.1. Analysis of DFA-PRO cocrystals by FTIR, DSC, and PXRD
The FTIR spectra of DFA, PRO, the physical mixture, and DFA-PRO
cocrystals (1:1) are presented in Fig. 2. Analysis of the spectrum of DFA
showed distinctive bands at 3324, 1693, and 937 cm−1, which re-
spectively represent OeH and CeO stretching of the carboxylic acid,
and OeH vibrations out of the plane from the carboxylic acid group.
The distinctive peaks of PRO were observed at 1619, 2348, and
3486 cm−1, representing CeO stretching of the carboxylic acid, NeH
stretching of the amine heterocyclic ring, and OeH stretching of the
carboxylic acid, respectively. As seen in Fig. 2, the spectrum of the
physical mixture of DFA and PRO clearly showed almost all the
characteristic bands of DFA and PRO.
The first peak represents the carbonyl group of the carboxylic acid
in DFA-PRO. Analysis of the spectra shows a wave number shift from
1693 cm−1 (DFA) to 1681 cm−1 (DFA-PRO) for the carbonyl group,
which is indicative of hydrogen bond formation between DFA and PRO.
This is supported by the shift in the wave number of the OH-free car-
boxylic acid in DFA from 3324 cm−1 to 3270 cm−1. The new broad
spectra at 1905 cm−1 and 2541 cm−1 were generated from the hy-
drogen bond in O…H-N (heterocyclic) or O-H…N (heterocyclic).
The DSC thermogram of DFA, PRO, and DFA-PRO cocrystals are
presented in Fig. 3. They clearly show that the melting point of DFA-
PRO cocrystals is lower than that of DFA (173.8 °C) or PRO (221.5 °C).
The X-ray diffractogram pattern of the DFA-PRO cocrystals was
compared to those of DFA, PRO, and a mixture of both (Fig. 4). The
results show that the diffraction pattern of the cocrystals is absolutely
different from that of the physical mixture. There were some char-
acteristic diffraction peaks at 2φ=4.29°, 9.73°, 11.54°, 13.18°, 14.31°,
19.42°, 20.48°, and 25.46°. On the other hand, characteristic diffraction
peaks of DFA and PRO are 2θ=10.79°, 13.31°, 15.10°, 18.82°, 24.34°
and 8.5°, 15.17°, 17.98°, 24.73°, respectively.
2.3.2. SCXRD analysis
The DFA-PRO cocrystals were needle-shaped (Fig. 5). DFA-PRO
crystallized in the monoclinic chiral P21 space group with one molecule
Fig. 2. FT-IR spectra of (a) DFA-PRO, (b) physical mixture of DFA and PRO (1:1), (c) PRO,
and (d) DFA.
Fig. 3. DSC thermograms of (a) DFA-PRO, (b) PRO, and (c) DFA.
Fig. 4. PXRD patterns of (a) DFA, (b) PRO, (c) physical mixture of DFA and PRO (1:1),
and (d) DFA-PRO cocrystals (1:1).
I. Nugrahani et al. European Journal of Pharmaceutical Sciences 117 (2018) 168–176
170
each of DFA and PRO in the asymmetric unit (Fig. 6). The details of
crystallographic data and refinement details of DFA-PRO shown in
Table. 1. The pyrrolidine ring of the PRO molecule is disordered with
the occupancy of major and minor parts determined at 0.85(2) and
0.15(2), respectively. Intramolecular N1–H1⋯O1 hydrogen bond
stabilizes the conformation of the DFA molecule. A similar conforma-
tion is observed in all three polymorphs of DFA (Castellari and Ottani,
1997; Jaiboon et al., 2001). Crystal structure analysis revealed that
DFA-PRO is a zwitterionic cocrystal. From the crystal structure, the
CeO distances between C14–O1 and C14–O2 in DFA are 1.225(6) Å and
1.311(5) Å, respectively. Since the difference in the CeO distance is
longer than 0.07 Å (ΔC–O > 0.07 Å), it confirms that the carboxylic
acid remains in the DFA molecule. In the PRO molecule, CeO distances
of the carboxylate are comparable, which are 1.258(5) Å and 1.251(6)
Å for C15–O3 and C15–O4, respectively, indicating its existence in
zwitterionic form.
Fig. 5. Micrographs of DFA-PRO cocrystals.
Fig. 6. Thermal ellipsoid drawing of the asymmetric unit in DFA-PRO drawn at 50% probability level. The dashed line indicates the minor part of disordered PRO.
Table 1
Crystallographic data and refinement details of DFA-PRO.
Parameter DFA-PRO
Moiety formula C14H11Cl2NO2, C5H9NO2
Formula weight 411.27
Crystal system Monoclinic
Space group P21
a (Å) 9.2875(7)
b (Å) 5.2245(5)
c (Å) 20.3755(17)
β (°) 102.284(3)
Volume (Å3) 966.04(14)
Z 2
T (K) 93(2)
Measured ref. 9569
Independent ref. 4183 [R(int) = 0.0553]
Refined parameter 265
Goodness-of-fit on F2 1.068
Final R indices [I > 2σ(I)] R1= 0.0518
CCDC deposit number 1584472
Table 2
Hydrogen bonds in DFA-PRO.
D–H⋯A D–H (Å) H⋯A (Å) D⋯A (Å) D–H⋯A (°)
N1–H1⋯Cl1c 0.89(8) 2.57(8) 3.013(4) 112(6)
N1–H1⋯O1c 0.89(8) 2.09(7) 2.846(5) 142(6)
N2–H2A⋯O4c 0.83(5) 2.25(5) 2.620(6) 107(4)
N2–H2B⋯O4a 0.82(6) 1.88(6) 2.694(6) 169(5)
N2–H2A⋯O1 0.83(5) 2.17(5) 2.819(5) 136(4)
O2–H2⋯O3b 0.87(3) 1.68(3) 2.543(5) 169(6)
C13–H13B⋯Cl1a 0.99 2.78 3.646(5) 145.9
a x, y− 1, z.
b −x+1, y− 1/2, −z.
c Intramolecular hydrogen bond.
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The details of the hydrogen bonds are presented in Table 2. DFA and
PRO formed an alternating layered structure (Fig. 7). The results show
that, in the crystal structure, DFA molecules are connected to two ad-
jacent PRO molecules via O2–H2⋯O3 and N2–H2A⋯O1 hydrogen
bonds. Furthermore, DFA and PRO molecules are arranged as a chain
structure along the crystallographic screw axis through C13–H13B···Cl1
and N2–H2B⋯O4 hydrogen bonds, respectively. The aforementioned
instances of hydrogen bonding in DFA-PRO are described in Fig. 8.
Details of the crystallographic data are listed in Table 1, whereas the
hydrogen bonds that support the new co-arrangement are explained in
Table 2.
Table 1 shows the crystal structure data as follows.
The hydrogen bond positions and its lengths are explained in
Table 2 below.
Fig. 7. Packing arrangement of DFA (yellow) and PRO (cyan) in DFA-PRO crystal structure (viewed along the b and a axes). The image shows an alternating layered structure. The minor
disordered part is omitted for clarity. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 8. Intermolecular interaction in DFA-PRO. The minor disordered parts are omitted for clarity. The symmetry codes are listed in Table 2.
Fig. 9. Solubility profiles of DFA and DFA-PRO cocrystals as obtained by liquid assisted
grinding.
Table 3
Powder solubility test results (n= 3).
Sample Solubility (μg/mL)
Pure diclofenac 16.56 ± 0.289
DFA-PRO obtained by liquid-assisted grinding 125.91 ± 0.322
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2.3.3. Powder solubility in water
The solubility profiles of diclofenac and its powder cocrystal are
presented in Fig. 9 and Table 3. The solubility data indicates the con-
centration of DFA in the solution to each sample. The solubility of pure
diclofenac and the cocrystal powder as shown in Table 3 are 16.56 μg/
mL and 125.91 μg/mL, or equivalent with 0.056mM and 0.425mM,
respectively. From the results, the aqueous solubility of DFA-PRO is the
7.69-fold higher than that of the active compound.
The enhanced solubility of the DFA-PRO cocrystal can be explained
according to its molecular arrangement and three-dimensional struc-
ture. Based on the data explained in Section 2.3.2, the layer structure of
DFA-PRO is the main factor that contributed to the solubility en-
hancement. The DFA molecule is present on the channel sandwiched
between two layers of PRO molecules. A similar molecular arrangement
has been reported for epalrestat caffeine cocrystal (Putra et al., 2017)
and naproxen-proline cocrystal (Tilborg et al., 2013). With such con-
figuration, water molecules easily interact with the PRO molecules,
resulting in a higher aqueous solubility (1300 g/L; Tilborg et al., 2014).
Moreover, once the PRO molecules dissolved, the DFA-PRO interaction
got broken, resulting in the exposure of the DFA molecules to the sol-
vent. The enhanced solubility indicates that the DFA-PRO cocrystal is a
promising candidate that can be developed into a solid dosage form.
Moreover, L-proline is a nutritional substance, a GRAS compound, and a
pharmacologically safe co-former (Wu et al., 2011); therefore, it is a
suitable component of the cocrystal.
Aakeröy et al. (2011) recently described the use of pyridine or
pyrimidine derivatives as co-formers in preparing diclofenac cocrystals;
however, pyridine and pyrimidine derivatives are toxic (Liu et al.,
1998; Sajewicz, 2007) to almost every vital organ in humans.
Fig. 10. Packing crystal structures of diclofenac-isonicotinamide (left) and DFA-PRO (right).
Fig. 11. Changes in the PXRD patterns of a physical mixture of DFA and PRO before and
after co-grinding.
Fig. 12. PXRD patterns for a series of DFA-PRO standards (left) and the calibration curve
obtained from them (right).
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Therefore, it is worth developing DFA-PRO cocrystals, which are a safer
alternative and have enhanced bioavailability and pharmacological
properties. Another recent report on diclofenac cocrystals is that by
Báthori et al. (2011), which is on diclofenac-isonicotinamide cocrystals.
Surov et al. (2014) also reported on diclofenac-theophylline cocrystal,
and indicated that the solubility of the cocrystal was only 1.6-fold
higher than that of pure diclofenac. The report on diclofenac-iso-
nicotinamide cocrystal does not include data on the solubility of the
cocrystal. According to the crystal structure, diclofenac-isonicotinamide
cocrystal is also a layered-structure cocrystal. As shown in Fig. 10, the
packing crystal structures of DFA-PRO and diclofenac-isonicotinamide
are similar. Although the aqueous solubility of isonicotinamide
(191.7 mg/mL) is higher than that of L-proline (162mg/mL), it is dif-
ficult to suggest that the aqueous solubility of diclofenac-iso-
nicotinamide is higher than that of DFA-PRO. Factors that influence the
solubility of substances in water include lattice energy, molecular
density, and co-former solubility (Good and Rodríguez-Hornedo, 2010).
2.3.4. Kinetics of cocrystallization
Cocrystals of DFA and PRO in equimolar amounts were formed by
liquid-assisted grinding at room temperature to have a detailed insight
into the kinetics of the co-grinding process during cocrystallization.
Changes in PXRD diffractogram during the process are seen in Fig. 11.
Significant changes in the PXRD diffractogram occurred during the
grinding process, which are indicative of the dynamic interaction be-
tween the molecules.
As seen in Fig. 11, there were several new reflection appearances
(marked with closed triangles) in the diffractogram. However, some
origin reflections disappeared (marked with dots). After 2min of
grinding, the characteristic reflections of DFA and PRO appeared pre-
dominantly at 2θ=10.60°, 15.16°, and 24.35° in the DFA diffracto-
gram, and at 2θ=8.53° and 19.15° in the PRO diffractogram. The
characteristic reflections of DFA-PRO cocrystal were also detected at
2θ=4.33° and 9.64°. As grinding time was increased, the intensity of
DFA-PRO increased, whereas that of both DFA and PRO decreased.
Finally, after 90min of grinding, the experimental diffractogram pat-
tern was similar to the reference patterns obtained after evaporating the
solvent from the single crystals. This indicated that the cocrystals had
been completely formed.
Quantification of cocrystal amount was done according to the
method described by Padrela et al. (2012). The initial step was selection
of the characteristic diffraction peaks of DFA-PRO, which are at
2θ=9.71, 14.47°, 19.07°, and 19.54°. The best regression line equation
for the quantification of DFA-PRO cocrystal was found to be
y= 7.2917x− 22.992. A high correlation coefficient of 0.9924 was
obtained. A diffractogram of a standard series of DFA-PRO cocrystals
Fig. 13. Formation of DFA-PRO cocrystals during co-grinding at room temperature. Data
are expressed as mean ± standard deviation (n=3).
Fig. 14. PXRD patterns of DFA-PRO cocrystals after storage at 30 °C under various RH conditions ((a) 75%, (b) 80%, and (c) 90% RH).
Fig. 15. Cocrystal content during storage at 30 °C under various RH conditions (75%,
80%, and 90% RH).
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and the corresponding calibration curve are shown in Fig. 12. The ca-
libration curve was used to determine the amount of the cocrystals (Wt
%).
The amounts of DFA-PRO cocrystals formed at specific times during
the grinding process are presented in Fig. 13. The amount of cocrystals
formed increased gradually as grinding time was increased. After 60
and 90min of grinding, the amounts obtained were 90.827 ± 1.284
and 90.878 ± 1.011%, respectively; however, the difference in the
yields was not statistically significant. This indicates that DFA-PRO
formation was complete after 60min of grinding. The PXRD results
obtained after 60min of grinding corroborate these findings since si-
milar diffractogram patterns were obtained for the cocrystals and single
crystals (Fig. 11).
Cocrystal formation rate followed a logarithmic function as follows:
y= 17.045 ln x+ 15.238. The correlation coefficient (R2) value was
0.9574, which indicates first-order kinetics. The content of the co-
crystals was not 90% after 90min of grinding. This may be due to the
use of the solvent to obtain the powder cocrystals by liquid-assisted
grinding. Furthermore, crystal defects or amorphous regions were de-
tected in the crystals due to the addition of solvent during the liquid-
assisted grinding process. Similar results were obtained during the
quantification of indomethacin-saccharin cocrystals produced by li-
quid-assisted grinding (Padrela et al., 2012).
2.3.5. Stability study
In order to ensure effective and widespread use of cocrystals, a
greater understanding of factors such as polymorphism and physical
stability is necessary (Eddleston et al., 2014). The stabilities of active
pharmaceutical ingredients (APIs) and dosage forms during distribution
and storage depend on two major factors: their chemical and physical
properties, and environmental factors. Pharmaceutical cocrystals ex-
hibit specific stability characteristics. For instance, certain APIs and co-
formers tend to dissociate during storage, particularly under high hu-
midity and temperature conditions. Additionally, removal or alteration
of a co-former in a cocrystal destroys the crystal arrangement and
changes the parent API to its original form (Hsu et al., 2012). Trask
et al. (2006) studied the stability of cocrystals of dicarboxylic acid,
caffeine, and theophylline at high humidity and found that the co-
crystals dissociated within seven days at 98% RH. This resulted in
crystallization of the acid and caffeine/theophylline hydrate as separate
phases. Due to the importance of stability in the development of new
cocrystals, the stability of the cocrystals was investigated at 30 °C under
various humidity conditions (75%, 80%, and 90% RH).
Fig. 13 shows diffractogram of the DFA-PRO cocrystals at 30 °C
during storage at 75%, 80%, or 90% RH for 24 h. The results indicate
that the cocrystals were relatively stable at 75% RH, as no changes in
pattern or intensity were observed (Fig. 14(a)). However, a propensity
for decomposition occurred at 80% RH and further increased at 90%
RH. After 24 h of storage at 80% RH, the cocrystals partially dis-
sociated, which was evidenced by a low trace intensities at 2θ=10.60°,
15.16°, 18.78°, and 23.50° in the diffractogram of DFA (Fig. 14(b)).
Moreover, diffraction of PRO was detected at 2θ=19.4°, 23.45°, and
25.46° at high intensities. A similar phenomenon was observed after
12 h of storage at 90% RH; however, the intensity was higher than that
at 80% RH. The findings show that the stability of DFA-PRO cocrystals
is influenced by humidity. However, no solid-state alteration of the
parent compound (i.e. polymorphism) was observed during the storage
period.
In order to further understand the dissociation of DFA-PRO due to
humidity, the amount of the cocrystals was measured after storage
under the various conditions. As shown in Fig. 15, the amount of the
cocrystals decreased gradually during storage, and the rate of decrease
was related to humidity. The dissociation reaction order followed a
first-order reaction at all conditions. This indicates that the dissociation
of DFA-PRO cocrystals is proportional to cocrystal concentration and
increases in a logarithmic order. The following logarithmic equations
were obtained at the various RH conditions.
= − + =y 9.08 ln x 78.009; R2 0.9705 (70%RH) (1)
= − + =y 13 ln x 85.608; R2 0.9039 (80%RH) (2)
= − + =y 22.6 ln x 95.364; R2 0.9555 (90%RH) (3)
The phenomenon observed in this experiment can be explained by
considering the humidity-induced dissociation of caffeine-theophylline
cocrystals reported by Trask et al. (2005). In an environment of high
humidity, the components of the DFA-PRO cocrystals tend to form
hydrated phases. If the free energy of the co-former or API hydrated
phase is lower than that of the cocrystal, separation of the two mole-
cules will be favored. Therefore, it could be presumed that dissociation
of DFA-PRO cocrystals under high humidity conditions is caused by the
presence of water, which is absorbed by L-proline to form a hydrate.
However, the exact mechanism underlying the dissociation of DFA-PRO
cocrystals in a humid environment is not completely explained by the
findings of the current study. Therefore, future studies on this should be
considered.
2.4. Conclusion
A new zwitterionic cocrystal of diclofenac and L-proline was suc-
cessfully formed and fully characterized in this study. The results
showed that the DFA-PRO cocrystals are needle-shaped with a layered
crystal structure that is advantageous in improving their aqueous so-
lubility. The cocrystals were found to be 7 times more soluble in water
than DFA. Furthermore, formation of the cocrystals was found to follow
first-order reaction kinetics. In the physical stability test, the DFA-PRO
cocrystals were found to be stable at 30 °C/75% RH; however, they
tended to dissociate into DFA and L-proline monohydrate at higher
humidity conditions (80% and 90% RH). The comprehensive char-
acterization conducted in this study can serve as a guide when de-
termining the physicochemical properties of zwitterionic cocrystals,
particularly when solubility and stability characteristics are desired.
Acknowledgement
This research was supported by World Class University Program:
International Research Collaboration between LPPM-ITB (Jawa Barat,
Indonesia) with Department of Chemistry and Material Science, Tokyo
Institute of Technology, Japan (grant number: 007/WCU-ITB/LL/III/
2017).
References
Aakeröy, C.B., Grommet, A.B., Desper, J., 2011. Co-crystal screening of diclofenac.
Pharmaceutics 3, 601–614. http://dx.doi.org/10.3390/pharmaceutics3030601.
Barbato, F., Cappello, B., La Rotonda, M.I., Miro, A., Quaglia, F., 2003. Diclofenac β-
cyclodextrin binary systems: a study in solution and in the solid state. J. Incl.
Phenom. Macrocycl. Chem. 46, 179–185. http://dx.doi.org/10.1023/
A:1026303516401.
Báthori, N.B., Lemmerer, A., Venter, G.A., Bourne, S.A., Caira, M.R., 2011.
Pharmaceutical co-crystals with isonicotinamide—vitamin B3, clofibric acid, and
diclofenac—and two isonicotinamide hydrates. Cryst. Growth Des. 11, 75–87. http://
dx.doi.org/10.1021/cg100670k.
Bhandaru, J.S., Malothu, N., Akkinepally, R.R., 2015. Characterization and solubility
studies of pharmaceutical cocrystals of eprosartan mesylate. Cryst. Growth Des. 15,
1173–1179. http://dx.doi.org/10.1021/cg501532k.
Bruno, I.J., Cole, J.C., Edgington, P.R., Kessler, M., Macrae, C.F., McCabe, P., Pearson, J.,
Taylor, R., 2002. New software for searching the Cambridge Structural Database and
visualizing crystal structures. Acta Crystallogr. B 58, 389–397. http://dx.doi.org/10.
1107/S0108768102003324.
Castellari, C., Ottani, S., 1997. Two monoclinic forms of diclofenac acid. Acta Crystallogr.
C Struct. Chem. 53, 794–797. http://dx.doi.org/10.1107/S0108270197002126.
Duggirala, N.K., Perry, M.L., Almarsson, Ö., Zaworotko, M.J., 2016. Pharmaceutical co-
crystals: along the path to improved medicines. Chem. Commun. 52, 640–655.
http://dx.doi.org/10.1039/C5CC08216A.
Eddleston, M.D., Thakuria, R., Aldous, B.J., Jones, W., 2014. An investigation of the
causes of cocrystal dissociation at high humidity. J. Pharm. Sci. 103, 2859–2864.
http://dx.doi.org/10.1002/jps.23865.
I. Nugrahani et al. European Journal of Pharmaceutical Sciences 117 (2018) 168–176
175
Fini, A., Cavallari, C., Ospitali, F., 2010. Diclofenac salts. V. Examples of polymorphism
among diclofenac salts with alkyl-hydroxy amines studied by DSC and HSM.
Pharmaceutics 2, 136–158. http://dx.doi.org/10.3390/pharmaceutics2020136.
Fini, A., Bassini, G., Monastero, A., Cavallari, C., 2012. Diclofenac salts, VIII. Effect of the
counterions on the permeation through porcine membrane from aqueous saturated
solutions. Pharmaceutics 4, 413–429. http://dx.doi.org/10.3390/
pharmaceutics4030413.
Good, D.J., Rodríguez-Hornedo, N., 2010. Cocrystal eutetic constants and prediction of
solubility behavior. Cryst. Growth Des. 10, 1028–1032. http://dx.doi.org/10.1021/
cg901232h.
He, H., Huang, Y., Zhang, Q., Wang, J.R., Mei, X., 2016. Zwitterionic cocrystals of fla-
vonoids and proline: solid-state characterization, pharmaceutical properties, and
pharmacokinetic performance. Cryst. Growth Des. 16, 2348–2356. http://dx.doi.org/
10.1021/acs.cgd.6b00142.
Higashi, T., 1995. ABSCOR. Rigaku Corporation, Tokyo, Japan.
Hsu, P.C., Lin, H.L., Wang, S.L., Lin, S.Y., 2012. Solid-state thermal behavior and stability
studies of theophylline–citric acid cocrystals prepared by neat cogrinding or thermal
treatment. J. Solid State Chem. 192, 238–245. http://dx.doi.org/10.1016/j.jssc.
2012.04.010.
Jaiboon, N., Yos-In, K., Ruangchaithaweesuk, S., Chaichit, N., Thutivoranath, R.,
Siritaedmukul, K., Hannongbua, S., 2001. New orthorhombic form of 2-[(2,6-di-
chlorophenyl)amino]benzeneacetic acid (diclofenac acid). Anal. Sci. 17, 1465–1466.
http://dx.doi.org/10.2116/analsci.17.1465.
Liu, S.M., Wu, C.H., Huang, H.J., 1998. Toxicity and anaerobic biodegradability of pyr-
idine and its derivatives under sulfidogenic conditions. Chemosphere 36, 2345–2357.
http://dx.doi.org/10.1016/S0045-6535(97)10203-X.
Liu, M., Hong, C., Yao, Y., Shen, H., Ji, G., Li, G., Xie, Y., 2016. Development of a
pharmaceutical cocrystal with solution crystallization technology: preparation,
characterization, and evaluation of myricetin-proline cocrystals. Eur. J. Pharm.
Biopharm. 107, 151–159. http://dx.doi.org/10.1016/j.ejpb.2016.07.008.
Macrae, C.F., Edgington, P.R., McCabe, P., Pidcock, E., Shields, G.P., Taylor, R., Towler,
M., van de Streek, J., 2006. Mercury: visualization and analysis of crystal structures.
J. Appl. Crystallogr. 39, 453–457. http://dx.doi.org/10.1107/S002188980600731X.
Macrae, C.F., Bruno, I.J., Chisholm, J.A., Edgington, P.R., McCabe, P., Pidcock, E.,
Rodriguez-Monge, L., Taylor, R., van de Streek, J., Wood, P.A., 2008. Mercury CSD
2.0 - new features for the visualization and investigation of crystal structures. J. Appl.
Crystallogr. 41, 466–470. http://dx.doi.org/10.1107/S0021889807067908.
Othman, M.F., Jamburi, N., Anuar, N., Abd Rahim, S., Rohalim, N.H., 2016. Ibuprofen-
amino acids co-crystal screening via co-grinding methods. MATEC Web Conf. 69,
03002. http://dx.doi.org/10.1051/matecconf/20166903002.
Padrela, L., de Azevedo, E.G., Velaga, S.P., 2012. Powder X-ray diffraction method for the
quantification of cocrystals in the crystallization mixture. Drug Dev. Ind. Pharm. 38,
923–929. http://dx.doi.org/10.3109/03639045.2011.633263.
Putra, O.D., Umeda, D., Nugraha, Y.P., Furuishi, T., Nagase, H., Fukuzawa, K., Uekusa, H.,
Yonemochi, E., 2017. Solubility improvement of epalrestat by layered structure
formation via cocrystallization. CrystEngComm 19, 2614–2622. http://dx.doi.org/
10.1039/C7CE00284J.
Qiu, J.B., Li, G., Sheng, Y., Zhu, M.R., 2015. Quantification of febuxostat polymorphs
using powder X-ray diffraction technique. J. Pharm. Biomed. Anal. 107, 298–303.
http://dx.doi.org/10.1016/j.jpba.2015.01.005.
Sajewicz, W., 2007. Toxicity of pyrimidine derivatives under oxidative stress conditions:
chemiluminescence-based assays in systems containing erythrocytes, mitochondria or
blood plasma. Pharmacol. Rep. 59, 206–215.
Sheldrick, G.M., 2015a. SHELXT - integrated space-group and crystal-structure determi-
nation. Acta Crystallogr., Sect. A: Found. Adv. 71, 3–8. http://dx.doi.org/10.1107/
S2053273314026370.
Sheldrick, G.M., 2015b. Crystal structure refinement with SHELXL. Acta Crystallogr. C
Struct. Chem. 71, 3–8. http://dx.doi.org/10.1107/S2053229614024218.
Silva, J.L.A.F., Santos, P.P., André, V., Galego, F., 2016. New cocrystals of flurbiprofen
and proline: structural effect of enantiomorphism. Acta Crystallogr., Sect. A: Found.
Adv. 72, s356. http://dx.doi.org/10.1107/S2053273316094730.
Surov, A.O., Voronin, A.P., Manin, A.N., Manin, N.G., Kuzmina, L.G., Churakov, A.V.,
Perlovich, G.L., 2014. Pharmaceutical cocrystals of diflunisal and diclofenac with
theophylline. Mol. Pharm. 11, 3707–3715. http://dx.doi.org/10.1021/mp5004652.
Tilborg, A., Springuel, G., Norberg, B., Wouters, J., Leyssens, T., 2013. On the influence of
using a zwitterionic coformer for cocrystallization: structural focus on naprox-
en–proline cocrystals. CrystEngComm 15, 3341–3350. http://dx.doi.org/10.1039/
C3CE40084K.
Tilborg, A., Norberg, B., Wouters, J., 2014. Pharmaceutical salts and cocrystals involving
amino acids: a brief structural overview of the state-of-art. Eur. J. Med. Chem. 74,
411–426. http://dx.doi.org/10.1016/j.ejmech.2013.11.045.
Tiwari, M., Chawla, G., Bansal, A.K., 2007. Quantification of olanzapine polymorphs
using powder X-ray diffraction technique. J. Pharm. Biomed. Anal. 43, 865–872.
http://dx.doi.org/10.1016/j.jpba.2006.08.030.
Trask, A.V., Samuel Motherwell, W.D., Jones, W., 2005. Pharmaceutical cocrystallization:
engineering a remedy for caffeine hydration. Cryst. Growth Des. 5, 1013–1021.
http://dx.doi.org/10.1021/cg0496540.
Trask, A.V., Sam Motherwell, W.D., Jones, W., 2006. Physical stability enhancement of
theophylline via cocrystallization. Int. J. Pharm. 320, 114–123. http://dx.doi.org/10.
1016/j.ijpharm.2006.04.018.
Williams, B.S., Buvanendran, A., 2011. Nonopioid analgesics: NSAIDs, COX-2 inhibitors,
and acetaminophen. In: Benzon, H., Raja, S.N., Fishman, S.M., Liu, S.S., Cohen, S.P.
(Eds.), Essentials of Pain Medicine. Elsevier, Philadelphia, pp. 130–139. http://dx.
doi.org/10.1016/B978-1-4377-2242-0.00026-2.
Wu, G., Bazer, F.W., Burghardt, R.C., Johnson, G.A., Kim, S.W., Knabe, D.A., Li, P., Li, X.,
McKnight, J.R., Satterfield, M.C., Spencer, T.E., 2011. Proline and hydroxyproline
metabolism: implications for animal and human nutrition. Amino Acids 40,
1053–1063. http://dx.doi.org/10.1007/s00726-010-0715-z.
I. Nugrahani et al. European Journal of Pharmaceutical Sciences 117 (2018) 168–176
176
